Effect of dibutyryl cyclic AMP on plasma renin activity in normal men and patients with primary aldosteronism.
Dibutyryl cyclic AMP (DBcAMP) directly stimulates the release of renin from the juxtaglomerular (JG) cells in vitro. We investigated the effect of DBcAMP on plasma renin activity (PRA) in 6 normal men and in 8 patients with primary aldosteronism (PA). A 20-min infusion of 0.33 mg/kg/min of DBcAMP significantly increased PRA in normal men, but had little effect on PRA in patients with PA. Infusion of DBcAMP significantly reduced the blood pressure and the levels of serum sodium and potassium in normal men and the patients with PA. Infusion of DBcAMP significantly increased urine volume in normal men, but not in patients with PA. Urinary excretion of sodium increased in both groups after the infusion of DBcAMP. Thus, DBcAMP did not stimulate renin release in patients with PA, suggesting that the chronic excess production of aldosterone suppresses the release of renin from JG cells.
Fukuda
N
N
Second Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Soma
M
M
Kubo
A
A
Kunimoto
M
M
Watanabe
Y
Y
Izumi
Y
Y
Kanmatsuse
K
K
D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D003994:Bucladesine / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood*; D012964:Sodium / Q000097:blood; D014556:Urine
D000450:Aldosterone; D003994:Bucladesine; D012964:Sodium; D012083:Renin; D011188:Potassium